On the stock market since 2021, it operates in the world of health and science. It has 2,903 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 12% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 19% a year on average.
The company sells $2.4B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $851.8M against $2.4B in annual sales.
The weight of investors positioned for a fall can be felt in the market.
On our five-subject report card, SHJBF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SHJBF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.